{"title":"基于glp -1的策略:不同作用模式的生理分析。","authors":"Rémy Burcelin, Pierre Gourdy, Stéphane Dalle","doi":"10.1152/physiol.00009.2013","DOIUrl":null,"url":null,"abstract":"<p><p>DPP4 inhibitors and GLP-1 receptor agonists used in incretin-based strategies treat Type 2 diabetes with different modes of action. The pharmacological blood GLP-1R agonist concentration targets pancreatic and some extrapancreatic GLP-1R, whereas DPP4i favors the physiological activation of the gut-brain-periphery axis that could allow clinicians to adapt the management of Type 2 diabetes, according to the patient's pathophysiological characteristics.</p>","PeriodicalId":520753,"journal":{"name":"Physiology (Bethesda, Md.)","volume":" ","pages":"108-21"},"PeriodicalIF":10.3000,"publicationDate":"2014-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1152/physiol.00009.2013","citationCount":"26","resultStr":"{\"title\":\"GLP-1-based strategies: a physiological analysis of differential mode of action.\",\"authors\":\"Rémy Burcelin, Pierre Gourdy, Stéphane Dalle\",\"doi\":\"10.1152/physiol.00009.2013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>DPP4 inhibitors and GLP-1 receptor agonists used in incretin-based strategies treat Type 2 diabetes with different modes of action. The pharmacological blood GLP-1R agonist concentration targets pancreatic and some extrapancreatic GLP-1R, whereas DPP4i favors the physiological activation of the gut-brain-periphery axis that could allow clinicians to adapt the management of Type 2 diabetes, according to the patient's pathophysiological characteristics.</p>\",\"PeriodicalId\":520753,\"journal\":{\"name\":\"Physiology (Bethesda, Md.)\",\"volume\":\" \",\"pages\":\"108-21\"},\"PeriodicalIF\":10.3000,\"publicationDate\":\"2014-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1152/physiol.00009.2013\",\"citationCount\":\"26\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Physiology (Bethesda, Md.)\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1152/physiol.00009.2013\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Physiology (Bethesda, Md.)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1152/physiol.00009.2013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
GLP-1-based strategies: a physiological analysis of differential mode of action.
DPP4 inhibitors and GLP-1 receptor agonists used in incretin-based strategies treat Type 2 diabetes with different modes of action. The pharmacological blood GLP-1R agonist concentration targets pancreatic and some extrapancreatic GLP-1R, whereas DPP4i favors the physiological activation of the gut-brain-periphery axis that could allow clinicians to adapt the management of Type 2 diabetes, according to the patient's pathophysiological characteristics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
